Company news

TuHURA Biosciences, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)

June 2, 2024

TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)

June 2, 2024

Kintara Therapeutics to Present at the Sidoti Micro-Cap Virtual Conference

May 7, 2023

Kintara Therapeutics to Present at the 2023 BIO CEO & Investor Conference

January 29, 2023

Kintara Therapeutics Receives Orphan Drug Designation for VAL-083 for Treatment of Diffuse Intrinsic Pontine Glioma (DIPG)

December 14, 2022

Kintara Therapeutics to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022

November 30, 2022

Kintara Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

November 29, 2022

Kintara Therapeutics Granted Fast Track Designation from FDA for REM-001 for Cutaneous Metastatic Breast Cancer

November 27, 2022

Kintara Therapeutics Presents Three Posters at the 2022 Society for Neuro-Oncology Annual Meeting

November 17, 2022

Kintara Announces One-for-Fifty Reverse Stock Split

November 10, 2022

Kintara Therapeutics Announces Fiscal 2023 First Quarter Financial Results and Provides Corporate Update

November 8, 2022

Kintara Therapeutics Pauses REM-001 Program to Conserve Funds to Support VAL-083 International Registrational Study

October 18, 2022

Kintara Therapeutics Announces Fiscal 2022 Financial Results and Provides Corporate Update

September 26, 2022

Kintara Therapeutics Announces Three Abstracts Have Been Accepted for the 2022 Society for Neuro-Oncology Annual Meeting

September 7, 2022

Kintara Therapeutics Receives Study May Proceed Letter from the FDA for REM-001 for Cutaneous Metastatic Breast Cancer

August 8, 2022

Kintara Therapeutics Enters Into Equity Purchase Agreement for Up to $20 Million with Lincoln Park Capital

August 2, 2022

Kintara Therapeutics to Present at the Alliance Global Partners Summer Healthcare Conference

June 20, 2022

Kintara Therapeutics to Present at the JMP Securities Life Sciences Conference

June 9, 2022

Kintara Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement

June 2, 2022

Kintara Announces First European Site Activation in Switzerland in GCAR Phase 2/3 Clinical Trial for Glioblastoma

May 26, 2022

Kintara Therapeutics Announces Fiscal 2022 Third Quarter Financial Results and Provides Corporate Update

May 12, 2022

← Newer news releases

Calls

Decks

The 5 newest of 7 decks. Every deck is listed under its year.